Table 3 Treatment related adverse events

From: Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial

Type of event

Total (n = 100)

Chemo-free (n = 21)

Chemo (n = 79)

All grades (%)

Grade  ≥  3 (%)

All grades (%)

Grade  ≥  3 (%)

All grades (%)

Grade  ≥  3 (%)

Total

90 (90.0)

35 (35.0)

15 (71.4)

3 (14.3)

75 (94.9)

32 (40.5)

Anemia

49 (49.0)

1 (1.0)

4 (19.0)

0 (0.0)

45 (57.0)

1 (1.3)

Alopecia

46 (46.0)

18 (18.0)

2 (9.5)

0 (0.0)

44 (55.7)

18 (22.8)

Neutropenia

46 (46.0)

16 (16.0)

2 (9.5)

1 (4.8)

44 (55.7)

15 (19.0)

Leukopenia

41 (41.0)

5 (5.0)

2 (9.5)

0 (0.0)

39 (49.4)

5 (6.3)

ALT increased a

24 (24.0)

3 (3.0)

4 (19.0)

0 (0.0)

20 (25.3)

3 (3.8)

AST increased a

18 (18.0)

2 (2.0)

5 (23.8)

0 (0.0)

13 (16.5)

2 (2.5)

Thrombocytopenia

15 (15.0)

3 (3.0)

1 (4.8)

0 (0.0)

14 (17.7)

3 (3.8)

Hyperglycemia

15 (15.0)

0 (0.0)

4 (19.0)

0 (0.0)

11 (13.9)

0 (0.0)

Fatigue

11 (11.0)

0 (0.0)

2 (9.5)

0 (0.0)

9 (11.4)

0 (0.0)

Hemoptysis

9 (9.0)

3 (3.0)

4 (19.0)

3 (14.3)

5 (6.3)

0 (0.0)

Fever

9 (9.0)

1 (1.0)

2 (9.5)

0 (0.0)

7 (8.9)

1 (1.3)

Lymphopenia

9 (9.0)

0 (0.0)

0 (0.0)

0 (0.0)

9 (11.4)

0 (0.0)

Cough

8 (8.0)

3 (3.0)

2 (9.5)

1 (4.8)

6 (7.6)

2 (2.5)

Creatinine increase

8 (8.0)

0 (0.0)

2 (9.5)

0 (0.0)

6 (7.6)

0 (0.0)

Peripheral neuropathy

7 (7.0)

0 (0.0)

0 (0.0)

0 (0.0)

7 (8.9)

0 (0.0)

Rash

6 (6.0)

1 (1.0)

1 (4.8)

0 (0.0)

5 (6.3)

1 (1.3)

Hypertriglyceridemia

5 (5.0)

0 (0.0)

2 (9.5)

0 (0.0)

3 (3.8)

0 (0.0)

Bacterial pneumonitis

5 (5.0)

4 (4.0)

2 (9.5)

1 (4.8)

3 (3.8)

3 (3.8)

Hyponatremia

4 (4.0)

0 (0.0)

0 (0.0)

0 (0.0)

4 (5.1)

0 (0.0)

Hypokalemia

4 (4.0)

0 (0.0)

0 (0.0)

0 (0.0)

4 (5.1)

0 (0.0)

Vomiting

4 (4.0)

0 (0.0)

0 (0.0)

0 (0.0)

4 (5.1)

0 (0.0)

Hypoalbuminemia

4 (4.0)

0 (0.0)

1 (4.8)

0 (0.0)

3 (3.8)

0 (0.0)

Decreased appetite

4 (4.0)

0 (0.0)

1 (4.8)

0 (0.0)

3 (3.8)

0 (0.0)

Constipation

3 (3.0)

0 (0.0)

0 (0.0)

0 (0.0)

3 (3.8)

0 (0.0)

Heart failure

2 (2.0)

1 (1.0)

0 (0.0)

0 (0.0)

2 (2.5)

1 (1.3)

Dyspepsia

2 (2.0)

0 (0.0)

2 (9.5)

0 (0.0)

0 (0.0)

0 (0.0)

Arthralgia

1 (1.0)

1 (1.0)

0 (0.0)

0 (0.0)

1 (1.0)

1 (1.0)

Diarrhea

1 (1.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (1.3)

0 (0.0)

Cerebral arterial insufficiency

1 (1.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (1.3)

0 (0.0)

Nausea

1 (1.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (1.3)

0 (0.0)

  1. aALT alanine transaminase, AST aspartate aminotransferase.
  2. See also Tables S6S7.